Skip to main content
Top
Published in: Supportive Care in Cancer 5/2007

01-05-2007 | Original Article

Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer

Authors: Catalina Lawsin, Katherine DuHamel, Steven H. Itzkowitz, Karen Brown, Helen Lim, Linda Thelemaque, Lina Jandorf

Published in: Supportive Care in Cancer | Issue 5/2007

Login to get access

Abstract

Goals of work

Complementary and alternative medicines (CAM) use among cancer patients is becoming more prevalent; however, our understanding of factors contributing to patients’ decisions to participate in CAM is limited. This study examined correlates of CAM use among colorectal cancer (CRC) survivors, an understudied population that experiences many physical and psychological difficulties.

Materials and methods

The sample was 191, predominantly white, CRC survivors (mean age = 59.9 ± 12.6) who were members of a colon disease registry at a NYC metropolitan hospital. Participants completed assessments of sociodemographic characteristics, psychosocial factors [e.g., psychological functioning, cancer specific distress, social support (SS), quality of life (QOL)], and past CAM use (e.g., chiropractic care, acupuncture, relaxation, hypnosis, and homeopathy).

Main results

Seventy-five percent of participants reported using at least one type of CAM; most frequently reported was home remedies (37%). Younger (p < 0.01) or female patients (p < 0.01) were more likely to participate in CAM than their older male counterparts. Among psychosocial factors, poorer perceived SS (p = 0.00), more intrusive thoughts (p < 0.05), and poorer overall perceived QOL (p < 0.05) were associated to CAM use. In a linear regression model (including age, gender, SS, intrusive thoughts, and perceived QOL), only age remained a significant predictor of CAM use.

Conclusion

These findings demonstrate that CAM use is prevalent among CRC survivors and should be assessed routinely by providers. CAMs may serve as a relevant adjunct to treatment among CRC patients as well as an indication of need for additional SS, especially among younger patients.
Literature
1.
go back to reference American Cancer Society (2005) Cancer facts & figures for African Americans 2005–2006. American Cancer Society, Atlanta, Georgia American Cancer Society (2005) Cancer facts & figures for African Americans 2005–2006. American Cancer Society, Atlanta, Georgia
2.
go back to reference Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H (2004) Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol 22(23):4829–4836, DecemberPubMedCrossRef Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H (2004) Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study. J Clin Oncol 22(23):4829–4836, DecemberPubMedCrossRef
3.
go back to reference Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv Data 27(343):1–19 Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv Data 27(343):1–19
4.
go back to reference Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340(22):1733–1739, June 3PubMedCrossRef Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340(22):1733–1739, June 3PubMedCrossRef
5.
6.
go back to reference Cohen S, Mermelstein R, Kamarck T, Hoberman HM (1985) Measuring the functional components of social support. In: Sarason IG, Sarason BR (eds) Social support: theory, research, and applications. Martinus Nijhoff, Dordrecht, pp. 73–94 Cohen S, Mermelstein R, Kamarck T, Hoberman HM (1985) Measuring the functional components of social support. In: Sarason IG, Sarason BR (eds) Social support: theory, research, and applications. Martinus Nijhoff, Dordrecht, pp. 73–94
7.
go back to reference Dunn J, Lynch B, Rinaldis M, Pakenham K, McPherson L, Owen N, Leggett B, Newman B, Atiken J (2006) Dimensions of quality of life and psychosocial variables most salient to colorectal cancer patients. Psycho-Oncology 15:20–30PubMedCrossRef Dunn J, Lynch B, Rinaldis M, Pakenham K, McPherson L, Owen N, Leggett B, Newman B, Atiken J (2006) Dimensions of quality of life and psychosocial variables most salient to colorectal cancer patients. Psycho-Oncology 15:20–30PubMedCrossRef
8.
go back to reference Ernst E, Cassileth BR (1999) How useful are unconventional cancer treatments? Eur J Cancer 35:1605–1613CrossRef Ernst E, Cassileth BR (1999) How useful are unconventional cancer treatments? Eur J Cancer 35:1605–1613CrossRef
9.
go back to reference Horowitz MJ (1982). Stress response syndromes and their treatment. In: Golderberger L, Breznitz S (eds) Handbook of stress: theoretical and clinical aspects. Free Press, New York, pp 711–732 Horowitz MJ (1982). Stress response syndromes and their treatment. In: Golderberger L, Breznitz S (eds) Handbook of stress: theoretical and clinical aspects. Free Press, New York, pp 711–732
10.
go back to reference Lu W (2005) Acupuncture for side effects of chemoradiation therapy in cancer patients. Sem Oncol Nurs 21(3):190–195, AugustCrossRef Lu W (2005) Acupuncture for side effects of chemoradiation therapy in cancer patients. Sem Oncol Nurs 21(3):190–195, AugustCrossRef
11.
go back to reference Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Platin N, Hummerston S, Scott JA, Panteli V, Gudmundsdottir G, Selvekerova S (2005) Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complement Ther Med 13(4):251–257 (December)PubMedCrossRef Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Platin N, Hummerston S, Scott JA, Panteli V, Gudmundsdottir G, Selvekerova S (2005) Complementary and alternative medicine use in colorectal cancer patients in seven European countries. Complement Ther Med 13(4):251–257 (December)PubMedCrossRef
12.
go back to reference Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dunser M, Richter R, Fleischhacker WW, Sperner-Unterweger B (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9(4):267–274PubMedCrossRef Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dunser M, Richter R, Fleischhacker WW, Sperner-Unterweger B (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9(4):267–274PubMedCrossRef
13.
go back to reference Norum J (1997) Adjuvant chemotherapy in Dukes’ B and C colorectal cancer has only a minor influence on psychological distress. Support Care Cancer 5(4):318–321PubMedCrossRef Norum J (1997) Adjuvant chemotherapy in Dukes’ B and C colorectal cancer has only a minor influence on psychological distress. Support Care Cancer 5(4):318–321PubMedCrossRef
14.
go back to reference Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 4(873):880 Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P (2000) Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer 4(873):880
15.
go back to reference Spiegel W, Zidek T, Vutuc C, Maier M, Isak K, Micksche M (2003) Complementary therapies in cancer patients: prevalence and patients’ motives. Weiner Klinische Wochenschrift 115(19–20):705–709CrossRef Spiegel W, Zidek T, Vutuc C, Maier M, Isak K, Micksche M (2003) Complementary therapies in cancer patients: prevalence and patients’ motives. Weiner Klinische Wochenschrift 115(19–20):705–709CrossRef
16.
go back to reference Sprangers MA, Taal BG, Aaronson NK, te Velde A (2006) Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum 38(4):361–369CrossRef Sprangers MA, Taal BG, Aaronson NK, te Velde A (2006) Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum 38(4):361–369CrossRef
17.
go back to reference Stewart A, Sherbourne D, Hayes R et al (1998) Psychological distress/well-being and cognitive functioning measures. In: Stewart A, Ware A (eds) Measuring functioning and well-being. Duke University Press, Durham Stewart A, Sherbourne D, Hayes R et al (1998) Psychological distress/well-being and cognitive functioning measures. In: Stewart A, Ware A (eds) Measuring functioning and well-being. Duke University Press, Durham
18.
go back to reference Tough SC, Johnston DW, Verhoef MJ, Arthur K, Bryant H (2002) Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Altern Ther Health Med 8:54–64PubMed Tough SC, Johnston DW, Verhoef MJ, Arthur K, Bryant H (2002) Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Altern Ther Health Med 8:54–64PubMed
19.
go back to reference Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A (2005) Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 4(4):274–286 (December 1)PubMedCrossRef Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A (2005) Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 4(4):274–286 (December 1)PubMedCrossRef
20.
go back to reference Walsh JM, Terdiman JP (2003) Colorectal cancer screening: clinical applications. JAMA 289:1297–1302PubMedCrossRef Walsh JM, Terdiman JP (2003) Colorectal cancer screening: clinical applications. JAMA 289:1297–1302PubMedCrossRef
21.
go back to reference Ware JE, Manning WG, Duan N et al (1984) Health status and the use of outpatient mental health services. Am Psychol 39:1090–1100PubMedCrossRef Ware JE, Manning WG, Duan N et al (1984) Health status and the use of outpatient mental health services. Am Psychol 39:1090–1100PubMedCrossRef
22.
go back to reference Wolsko PM, Eisenberg DM, Davis RB, Ettner SL, Phillips RS (2002) Insurance coverage, medical conditions, and visits to alternative medicine providers: results of a national survey. Arch Intern Med 162(3):281–287 (February 11)PubMedCrossRef Wolsko PM, Eisenberg DM, Davis RB, Ettner SL, Phillips RS (2002) Insurance coverage, medical conditions, and visits to alternative medicine providers: results of a national survey. Arch Intern Med 162(3):281–287 (February 11)PubMedCrossRef
23.
go back to reference Yates JS, Mustian KM, Morrow GR, Gilles LJ, Padmanahan D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13(10):806–811PubMedCrossRef Yates JS, Mustian KM, Morrow GR, Gilles LJ, Padmanahan D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13(10):806–811PubMedCrossRef
Metadata
Title
Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer
Authors
Catalina Lawsin
Katherine DuHamel
Steven H. Itzkowitz
Karen Brown
Helen Lim
Linda Thelemaque
Lina Jandorf
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0198-3

Other articles of this Issue 5/2007

Supportive Care in Cancer 5/2007 Go to the issue

Forthcoming Meetings

Forthcoming Meetings

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine